Form 8 (OPD) (Midatech Pharma plc), Midatech Pharma PLC, 2020-05-04

RNS Number : 7369L

Midatech Pharma PLC

04 May 2020

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Midatech Pharma plc (“Midatech”)
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	Midatech Pharma plc
(d) Is the discloser the offeror or the offeree?	OFFEROR / OFFEREE
(e) Date position held: The latest practicable date prior to the disclosure	1 May 2020
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”	YES / NO / N/A If YES, specify which:

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	n/a		n/a
(2) Cash-settled derivatives:	n/a		n/a
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	n/a		n/a
TOTAL:	n/a		n/a

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities

Class of relevant security in relation to which subscription right exists:	n/a
Details, including nature of the rights concerned and relevant percentages:	n/a

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors’ and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Interest of Midatech Directors and connected advisers in Midatech shares:

Name	Number of Shares	% of issued share capital
Rolf Stahel	53,853	0.23
Stephen Stamp	50,000	0.21
Sijmen De Vries	26,242	0.11
Simon Turton	55,325	0.24

Interest of Midatech Directors in warrants over Midatech shares:

Name	Number of Warrants	Exercise price	Expiry date
Rolf Stahel	23,856	£10.00	26/02/2022
Sijmen De Vries	21,345	£10.00	26/02/2022
Simon Turton	41,855	£10.00	26/02/2022

Interest of Midatech Directors in options over Midatech shares:

Name	No. of options	Exercise price	Vesting date	Expiry date
Stephen Stamp	50,000	£1.05	20,000 if >$20m raised before 08/09/20, 7,500 on 09/09/20, 1,875 each of 12 quarters ending 09/12/23	02/10/2029
Sijmen de Vries	200	£83.80	Vested	20/04/2022
Sijmen de Vries	500	£1.50	Based on share price: 50% at £106.20; 25% at £274.40; 25% at £377.20	30/06/2024

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	YES/NO
Supplemental Form 8 (SBL)	YES/NO

Date of disclosure:

4 May 2020

Contact name:

Stephen Stamp

CEO/CFO

Telephone number:

+44 (0)1235 888300

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

FEESSFFEDESSEFI

Date of disclosure:

Contact name:

Telephone number:

Leave a Reply Cancel Reply